Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement (reformatted version of article & suppl tables)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huntington Study Group,
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huntington Study Group,
Related Collections
Right arrow Huntington's disease
Right arrow All Clinical trials
Right arrow Clinical trials Randomized controlled (CONSORT agreement)
NEUROLOGY 2004;63:547-549
© 2004 American Academy of Neurology
Brief Communications

Minocycline safety and tolerability in Huntington disease

Huntington Study Group*

Address correspondence and reprint requests to Dr. M. Cudkowicz, Neurology Clinical Trial Unit, Massachusetts General Hospital, 13 St., Bldg. 149, Rm. 2274, Charlestown, MA 02129; e-mail: mcudkowicz{at}partners.org

Minocycline is an antibiotic with anti-inflammatory and antiapoptotic properties that prolongs survival in a transgenic Huntington disease (HD) mouse model. In a double-blind, randomized, placebo-controlled study of minocycline in 60 HD patients, the authors determined that over 8 weeks, minocycline at 100 and 200 mg/day was well tolerated and safe in HD patients. Tolerability and adverse event frequency were similar between treatment and placebo groups.

Received January 13, 2004. Accepted in final form March 22, 2004.

Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the August 10 issue to the find the title link for this article.

*See theAppendix on page 548 for a list of Group members.




This article has been cited by other articles:


Home page
 BrainHome page
Y. F. Tai, N. Pavese, A. Gerhard, S. J. Tabrizi, R. A. Barker, D. J. Brooks, and P. Piccini
Microglial activation in presymptomatic Huntington's disease gene carriers
Brain, July 1, 2007; 130(7): 1759 - 1766.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
N. Pavese, A. Gerhard, Y. F. Tai, A. K. Ho, F. Turkheimer, R. A. Barker, D. J. Brooks, and P. Piccini
Microglial activation correlates with severity in Huntington disease: A clinical and PET study
Neurology, June 13, 2006; 66(11): 1638 - 1643.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
B. C. Hains and S. G. Waxman
Activated microglia contribute to the maintenance of chronic pain after spinal cord injury.
J. Neurosci., April 19, 2006; 26(16): 4308 - 4317.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by AAN Enterprises, Inc.